TABLE 2.
Frequencies of mutations associated with resistance to zidovudine and lamivudine in clinical isolates (n = 307), ranked with increasing resistance to abacavir
| Fold reduced susceptibility to abacavira | Frequency (%) of mutations associated with resistance to zidovudine and lamivudine (19)
|
No. of samples | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M41L | E44D/A | D67N | K70R | V1181 | M184V/I | H208Y | L210W | R211K | L214F | T215Y/F/C | K219Q/E/R | ||
| <2.5 | 17.7 | 3.1 | 14.6 | 9.4 | 5.2 | 11.5 | 2.1 | 9.4 | 43.8 | 88.5 | 24.0 | 12.5 | 96 |
| 2.5–5.5 | 55.0 | 17.5 | 45.0 | 22.5 | 21.3 | 43.8 | 16.3 | 30.0 | 51.3 | 88.8 | 57.5 | 21.3 | 80 |
| >5.5 | 76.3 | 32.8 | 54.2 | 19.9 | 31.3 | 71.0 | 20.6 | 67.2 | 71.0 | 87.8 | 80.9 | 31.3 | 131 |
a
Fold increase in IC50 of the respective recombinant virus compared to the IC50 of the nonresistant reference virus NL4-3.